This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.
ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization
by Zacks Equity Research
ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.
Zimmer Biomet (ZBH) Receives FDA Nod for ROSA Hip System
by Zacks Equity Research
The recent FDA go-ahead for Zimmer Biomet's (ZBH) ROSA Hip System will aid surgeons perform robotically-assisted direct anterior total hip replacement surgery.
Here's Why You Should Hold on to LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.
Merit Medical (MMSI) Expands Drainage Portfolio With New Product
by Zacks Equity Research
Merit Medical's (MMSI) new commercial product launch can make sample collection simple, safe and efficient.
Hill-Rom (HRC) PSS Growth Solid Despite Tough Y/Y Comparison
by Zacks Equity Research
Hill-Rom's (HRC) recent launches, including the Helion Integrated Surgical System in the United States, buoy optimism.
Abbott (ABT) Receives FDA Nod for Amplatzer Amulet Device
by Zacks Equity Research
The FDA's go-ahead for Abbott's (ABT) Amulet will offer a unique treatment option in the United States that seals off the left atrial appendage entirely without any blood-thinning drugs.
Here's Why You Should Retain Glaukos (GKOS) Stock Right Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
OPKO Health's (OPK) Arm Boosts Prenatal Screening With Buyout
by Zacks Equity Research
OPKO Health's (OPK) BioReference's acquisition to expand its NIPS offerings and thereby enhance prenatal screening.
Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance across the Life Science and Clinical Diagnostics businesses drove the top line for Bio-Rad (BIO).
Ecolab (ECL) Inks New Innovative Deal With Manchester United
by Zacks Equity Research
Ecolab (ECL) collaborates with Manchester United (MANU) to advance hygiene and sustainable practices across Old Trafford and the Carrington training ground.
Cooper Companies (COO) Unit's MiSight Gets Approval in China
by Zacks Equity Research
CooperVision, a unit of Cooper Companies (COO), receives approval for MiSight 1 day contact lenses from China's National Medical Products Administration for use in China.
Omnicell (OMCL) Rides on New Buyout, Innovation Amid Pandemic
by Zacks Equity Research
Omnicell (OMCL) accelerates shift to cloud-based solutions and tech-enabled services through the launches of Omnicell One and Central Pharmacy Dispensing Services.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum on the back of a solid product portfolio and improving margins. However, forex woes linger.
Quest Diagnostics (DGX), eMed Deal to Boost BinaxNOW Sales
by Zacks Equity Research
Under the collaboration, eMed's Certified Guide will supervise Quest Diagnostics' (DGX) BinaxNOW home testing process virtually.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Strong fiscal fourth-quarter performance in the Food Safety and Animal Safety segments drove the top line for Neogen (NEOG).
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong segmental growth and raised Roto-Rooter and earnings guidance for 2021.
Here's Why You Should Invest in Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System.
7 Low Price-to-Book Value Picks for August
by Kinjel Shah
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Medtronic (MDT) to Expand Neuroscience Line With XENT Buyout
by Zacks Equity Research
Medtronic's (MDT) acquisition of Intersect ENT is intended to offer a wide-ranging variety of solutions to help surgeons treat CRS patients.
Zimmer Biomet (ZBH) Recovery Rate Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) sees slower recovery amid the emergence of a new strain of coronavirus in a number of markets, including Japan.
Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO) backed by strong segmental performance across geographies in the second quarter and raised 2021 guidance.
NVST or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Abbott (ABT) Receives FDA Approval for OCT Imaging Platform
by Zacks Equity Research
The FDA authorization for Abbott's (ABT) OCT imaging platform powered by the Ultreon Software is expected to broaden its accessibility to physicians.
Envista (NVST) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 20.46% and 4.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?